[Editor Note: This section is applicable to all applications with a filing date, or, for national phase applications, an international filing date, on or after July 1, 2022, having disclosure of one or more nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). ]

37 C.F.R. 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.

1. *****

2. (f) "Amino acid" includes any D- or L-amino acid or modified amino acid as defined in paragraph 3(a) of WIPO Standard ST.26.

3. *****

WIPO Standard ST.26, paragraph 3(a), defines "amino acid" to mean any amino acid that can be represented using any of the symbols shown in Annex I, Table 3: List of Amino Acids Symbols of WIPO Standard ST.26 (reproduced in MPEP § 2412.03(a)). Such amino acids include, inter alia, D-amino acids and amino acids containing modified or synthetic side chains. Amino acids will be construed as unmodified L-amino acids unless further described in a "feature table". See MPEP § 2413.01(g), subsection I, for discussion of a "feature table". A peptide nucleic acid (PNA) residue is not considered an amino acid, but is considered a nucleotide.